S 1276 115th Congress Senate Crime and Law Enforcement Alternative treatments Child health Drug therapy Drug trafficking and controlled substances Education programs funding Government studies and investigations Health personnel Health programs administration and funding Higher education Licensing and registrations Medical education Medical research Neurological disorders Research administration and funding Trade restrictions

Cannabidiol Research Expansion Act

Introduced: May 25, 2017 See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

May 25, 2017

Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221)

May 25, 2017

Introduced in Senate

Plain-English summary Congressional Research Service

Cannabidiol Research Expansion Act

This bill requires the Drug Enforcement Administration (DEA) and the Department of Health and Human Services to each evaluate whether cannabidiol, the nonpsychoactive substance derived from marijuana or the synthetic formulation, should be a controlled substance under the Controlled Substances Act. After taking into consideration the evaluations, the DEA must initiate proceedings for classifying cannabidiol as a controlled substance if control is warranted.

The bill expands the authority for: (1) conducting medical research on cannabidiol and other nonpsychoactive components of marijuana, and (2) possessing or transporting cannabidiol or any other nonpsychoactive component of marijuana for certain medicinal purposes.

The Department of Justice shall register an applicant to manufacture or distribute cannabidiol or marijuana for the purpose of commercial production if approved by HHS.

Physicians who are licensed under state law may discuss the potential harms and benefits of cannabidiol or those components of marijuana as a treatment with their patients or the legal guardians of underage patients.

The bill terminates four years after enactment.

What's happening now May 25, 2017

Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221)

Committees of jurisdiction 1